#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Lupus nephritis Central nervous system neoplasm Breast angiosarcoma Biotinidase deficiency C3 glomerulopathy Fontan procedure Germ cell cancer Immunoglobulin G4 related disease Inflammatory myofibroblastic tumour Squamous cell carcinoma of head and neck Synovitis Rectal cancer Neuroendocrine carcinoma metastatic Rhabdomyosarcoma recurrent Epilepsy More trials…

    Learn about Rare Diseases

    Activated PI3 kinase delta syndrome – Life with Disease Alport’s syndrome – Treatment Indolent systemic mastocytosis – Treatment Nephrotic syndrome – Diagnostics Chondrosarcoma metastatic – Trials in Disease CADASIL – Basic Information Shprintzen-Goldberg syndrome – Diagnostics Marginal zone lymphoma refractory – Life with Disease Familial haemophagocytic lymphohistiocytosis Mucopolysaccharidosis II – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Zofenopril Calcium Opelconazole MOLNUPIRAVIR Bleomycin Sulfate Ebastine Linerixibat Thiamine Oxygen Ph.eur. Cabotegravir Sodium Vudalimab GSKVX000000025896 Quizartinib Dihydrochloride Ublituximab Benfotiamine Agomelatine A24110He ROPINIROLE Raludotatug Deruxtecan Lidocaine Efgartigimod Alfa More therapies…

    Learn about Your Condition

    Diabetic nephropathy Pericarditis Mixed dementia Non-Hodgkin's lymphoma Clostridium difficile colitis Red blood cell abnormality Tuberculosis Oral neoplasm Nephrotic syndrome Clinically isolated syndrome Obstructive airways disorder Hydrocephalus Gender dysphoria Hepatobiliary cancer Gouty arthritis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Mucopolysaccharidosis II

  • Study on the Effectiveness and Safety of DNL310 vs Idursulfase for Children and Young Adults with Mucopolysaccharidosis Type II

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Mucopolysaccharidosis II
    Investigated Drugs:
    • Iduronate-2-Sulfatase Fused To A Fc Polypeptide That Binds To The Human Transferrin Receptor
    • Idursulfase
    Belgium Czechia France Germany Italy The Netherlands +2

  • Study on Long-Term Safety of Idursulfase-IT and Elaprase for Patients with Hunter Syndrome and Cognitive Impairment

    Recruiting

    3 1 1
    Investigated Diseases:
    • Mucopolysaccharidosis II
    Investigated Drugs:
    • Idursulfase
    France

  • Long-term Safety and Efficacy Study of JR-141 (Pabinafusp Alfa) for Male Patients with Hunter Syndrome (Mucopolysaccharidosis II)

    Recruiting

    3 1 1
    Investigated Diseases:
    • Mucopolysaccharidosis II
    Investigated Drugs:
    • Pabinafusp Alfa
    France Germany Italy Poland Spain

  • Study on Long-Term Safety and Effects of DNL310 for Patients with Mucopolysaccharidosis Type II (MPS II)

    Recruiting

    3 1 1
    Investigated Diseases:
    • Mucopolysaccharidosis II
    Investigated Drugs:
    • Iduronate-2-Sulfatase Fused To A Fc Polypeptide That Binds To The Human Transferrin Receptor
    Belgium Czechia France Germany Italy The Netherlands +2

  • Study on the Effects and Safety of JR-141 and Idursulfase for Patients with Hunter Syndrome

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Mucopolysaccharidosis II
    Investigated Drugs:
    • Idursulfase
    • Pabinafusp Alfa
    France Germany Italy Poland Spain

  • Study on the Safety of DNL310 for Children with Hunter Syndrome

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Mucopolysaccharidosis II
    Investigated Drugs:
    • Iduronate-2-Sulfatase Fused To A Fc Polypeptide That Binds To The Human Transferrin Receptor
    The Netherlands

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!